No abstract

Background: Recent studies have demonstrated a correlation between intestinal flora and the severity of myocardial infarction as well as post-myocardial infarction repair. However, few studies have investigated whether probiotics reduce mortality and improve cardiovascular outcomes in patients with acute myocardial infarction. In this study, we will conduct a randomized controlled trial (RCT) to evaluate the effect of probiotics on in-hospital mortality and incidence of major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI). Methods: This is an open-label, randomized, controlled, superiority clinical trial involving 2594 adult patients who diagnosed with acute myocardial infarction. Patients will be randomized to (1)receive bifidobacteria triple viable capsule (Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis) 840 mg, twice a day, plus standard treatment strategy during the hospital stay , for a maximum of 30 days, or (2)receive the standard treatment strategy and will not take the bifidobacterium triple live capsule. The primary outcome was in-hospital all-cause mortality. Discussion: The purpose of this clinical trial is to determine whether probiotics can reduce in-hospital mortality and improve prognosis in patients with AMI, and the results will provide evidence for probiotics as a complementary treatment for AMI. Trial registration: Chinese Clinical Trials Registry ChiCTR2000038797. Registered on 2 October 2020.